While the results of evolutionRMS, comparing evobrutinib with teriflunomide, were negative, that "doesn't mean that evobrutinib is not working," said Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat).
Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat), discussed the designs and findings of the phase 3 evolutionRMS (relapsing multiple sclerosis) 1 and 2 trials, which he presented during the "Late-Breaking Research & Clinical Trials" session at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 on March 2.
Also, although the study population consisted of patients from 52 different countries, Montalban explained that there were no variations in treatment responses.
Transcript
Can you explain the design of the phase 3 evolutionRMS 1 and 2 trials?
They are 2 identical phase 3 trials that were blind. We used them to compare teriflunomide against evobrutinib. More than 1200 patients were recruited in each of the trials. It was a large, large trial, and the duration was about 156 weeks.
Could you please summarize the findings of these trials?
The trial was essentially negative. Evobrutinib didn't show any positive results in relation to teriflunomide for annualized relapse rate, which was the primary end point, or any of the secondary end points, such as confirmed disability progression, confirmed disability improvement, or MRI [magnetic resonance imaging] parameters.
This doesn't mean that evobrutinib is not working. It does work as well as teriflunomide, but we have to say that the trial is definitely negative.
Considering the study population consisted of patients across 52 countries, were there variations in treatment responses or safety outcomes based on geographic regions or demographic factors?
Remember that we had 2 big events during the trial. One was the pandemic and the other was the Ukraine-Russia conflict. In the end, quite a large proportion of patients came from eastern Europe, especially from Ukraine and Russia, but the Merck team managed the situation very well. When you compare patients coming from those areas to patients coming from other areas in the world, there are no differences at all. I think there is no influence at all on the final result of the trials.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More